These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25502587)

  • 21. New oral anticoagulants for the treatment of venous thromboembolism.
    Agnelli G; Becattini C; Franco L
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population.
    Wells PS; Prins MH; Beyer-Westendorf J; Lensing AWA; Haskell L; Levitan B; Laliberté F; Ashton V; Xiao Y; Lejeune D; Crivera C; Lefebvre P; Zhao Q; Yuan Z; Schein J; Prandoni P
    Chest; 2018 Dec; 154(6):1371-1378. PubMed ID: 30201406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
    Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
    J Med Econ; 2013 Sep; 16(9):1163-8. PubMed ID: 23869941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment with novel oral anticoagulants: indications, efficacy and risks.
    Ghanny S; Crowther M
    Curr Opin Hematol; 2013 Sep; 20(5):430-6. PubMed ID: 23852184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness Evaluations Among the Direct Oral Anticoagulants for the Prevention and Treatment of Venous Thromboembolism: Systematic Review.
    Al Mukdad M; Al-Badriyeh D; Elewa HF
    Clin Appl Thromb Hemost; 2019; 25():1076029619849103. PubMed ID: 31088296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.
    Monreal M; Folkerts K; Diamantopoulos A; Imberti D; Brosa M
    Thromb Haemost; 2013 Nov; 110(5):987-94. PubMed ID: 23965805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting.
    Jugrin AV; Hösel V; Ustyugova A; De Francesco M; Lamotte M; Sunderland T
    J Med Econ; 2016; 19(1):1-10. PubMed ID: 26390231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
    Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.
    Cohen AT; Dobromirski M
    Thromb Haemost; 2012 Jun; 107(6):1035-43. PubMed ID: 22371186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK.
    Jugrin AV; Ustyugova A; Urbich M; Lamotte M; Sunderland T
    Thromb Haemost; 2015 Oct; 114(4):778-92. PubMed ID: 26272227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
    Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
    J Med Econ; 2011; 14(6):824-34. PubMed ID: 22023098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands.
    Stevanović J; de Jong LA; Kappelhoff BS; Dvortsin EP; Voorhaar M; Postma MJ
    PLoS One; 2016; 11(10):e0163550. PubMed ID: 27776137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.
    Revankar N; Patterson J; Kadambi A; Raymond V; El-Hadi W
    Postgrad Med; 2013 Jul; 125(4):141-53. PubMed ID: 23933902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.
    Sardar P; Chatterjee S; Lavie CJ; Giri JS; Ghosh J; Mukherjee D; Lip GY
    Int J Cardiol; 2015 Jan; 179():279-87. PubMed ID: 25464465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meta-analysis on efficacy and safety of new oral anticoagulants for venous thromboembolism prophylaxis in elderly elective postarthroplasty patients.
    Pathak R; Giri S; Karmacharya P; Aryal MR; Poudel DR; Ghimire S; Jehangir A; Shaikh B; Rettew A; Donato AA
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):934-9. PubMed ID: 26258674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-vitamin K antagonist oral anticoagulants for the prevention of recurrent venous thromboembolism.
    Bauersachs R
    Thromb Res; 2016 Aug; 144():12-20. PubMed ID: 27263046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Healthcare costs associated with rivaroxaban or warfarin use for the treatment of venous thromboembolism.
    Coleman CI; Baugh C; Crivera C; Milentijevic D; Wang SW; Lu L; Nelson WW
    J Med Econ; 2017 Feb; 20(2):200-203. PubMed ID: 27780397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
    J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of apixaban compared to low-molecularweight heparins and vitamin k antagonists for treatment and secondary prevention of venous thromboembolism.
    Elías I; Oyagüez I; Alvarez-Sala LA; García-Bragado F; Navarro A; González P; De Andrés-Nogales F; Soto J
    Farm Hosp; 2016 May; 40(3):187-208. PubMed ID: 27145388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.